Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
CPIX 
Cumberland Pharmaceuticals Inc (CPIX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: CPIX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8.5
1 Year Target Price $8.5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -8.6% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 35.75M USD | Price to earnings Ratio - | 1Y Target Price 8.5 |
Price to earnings Ratio - | 1Y Target Price 8.5 | ||
Volume (30-day avg) 1 | Beta -0.45 | 52 Weeks Range 1.19 - 7.25 | Updated Date 12/6/2025 |
52 Weeks Range 1.19 - 7.25 | Updated Date 12/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.24 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -8.06% | Operating Margin (TTM) -23.7% |
Management Effectiveness
Return on Assets (TTM) -2.86% | Return on Equity (TTM) -13.28% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 29142310 | Price to Sales(TTM) 0.87 |
Enterprise Value 29142310 | Price to Sales(TTM) 0.87 | ||
Enterprise Value to Revenue 0.71 | Enterprise Value to EBITDA 9.82 | Shares Outstanding 14956627 | Shares Floating 8733324 |
Shares Outstanding 14956627 | Shares Floating 8733324 | ||
Percent Insiders 41.63 | Percent Institutions 22.93 |
Upturn AI SWOT
Cumberland Pharmaceuticals Inc
Company Overview
History and Background
Cumberland Pharmaceuticals Inc. was founded in 1999 and is headquartered in Nashville, Tennessee. It is a specialty pharmaceutical company focused on developing, acquiring, and commercializing branded prescription products.
Core Business Areas
- Hospital Products: This segment focuses on products used in acute care settings, such as hospital pharmacies and intensive care units. Examples include Vibativ, Caldolor, and Ofirmev.
- Gastroenterology Products: This segment includes products for the treatment of gastrointestinal disorders. Examples include Kristalose and GoLYTELY.
- Women's Health: This segment includes products focused on the health and well being of women.
Leadership and Structure
The leadership team includes Steven A. Stutts (Chief Executive Officer), and numerous other senior executives overseeing different departments. The organizational structure follows a typical pharmaceutical company model with departments for R&D, marketing, sales, and finance.
Top Products and Market Share
Key Offerings
- Ofirmev (acetaminophen): An intravenous acetaminophen injection for pain and fever reduction. It is widely used in hospitals. Competitors include generic IV acetaminophen products. Market share data and revenue for this product is not publicly available. Exact market share data is proprietary. Likely competitors include companies making generic IV acetaminophen.
- Caldolor (ibuprofen): An intravenous ibuprofen injection for pain and fever reduction. Market share data and revenue for this product is not publicly available. Exact market share data is proprietary. Likely competitors include companies developing alternate IV NSAIDs and analgesics.
- Vibativ (telavancin): An injectable antibiotic for the treatment of certain bacterial infections. Market share data and revenue for this product is not publicly available. Exact market share data is proprietary. Competitors include other branded and generic injectable antibiotics such as Vancomycin.
- Kristalose (lactulose): For the treatment of hepatic encephalopathy (HE) Market share data and revenue for this product is not publicly available. Exact market share data is proprietary. Competitors include generics lactulose products.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly regulated and competitive, characterized by significant R&D costs, patent protection, and generic erosion. Trends include increasing focus on specialty drugs, biosimilars, and value-based pricing.
Positioning
Cumberland Pharmaceuticals positions itself as a specialty pharmaceutical company focusing on niche markets and hospital products. Its competitive advantage lies in its established product portfolio and sales force targeting hospitals.
Total Addressable Market (TAM)
The TAM for Cumberland's products is in the billions of dollars when considering the overall acute care and GI markets. Cumberland is positioned to capture a portion of this TAM through its focused product portfolio and sales efforts.
Upturn SWOT Analysis
Strengths
- Established product portfolio
- Experienced sales force targeting hospitals
- Focus on niche markets
- Strong R&D capabilities for specialty drugs
- Patents and Exclusivity on Products
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on a small number of key products
- Exposure to generic competition
- Regulatory hurdles and compliance costs
- Limited Geographic Diversification
Opportunities
- Acquisition of new products or companies
- Expansion into new geographic markets
- Development of innovative therapies
- Partnerships with other pharmaceutical companies
- Leveraging technology for drug discovery
Threats
- Generic competition
- Pricing pressures from payers
- Regulatory changes
- Product liability lawsuits
- Economic Downturn
Competitors and Market Share
Key Competitors
- Endo International (ENDP)
- Mallinckrodt (MNK)
- Bausch Health Companies Inc. (BHC)
Competitive Landscape
Cumberland faces competition from both branded and generic pharmaceutical companies. Its smaller size and focus on niche markets can be both an advantage and a disadvantage. Key competitive factors include product differentiation, pricing, and distribution.
Major Acquisitions
The I.V. Acetaminophen product line, including Ofirmev
- Year: 2014
- Acquisition Price (USD millions): 250
- Strategic Rationale: Expanded Cumberland's product portfolio in the hospital segment and provided immediate revenue generation.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been variable, dependent on new product launches and acquisitions.
Future Projections: Future projections are not available without access to real-time data and analysis from financial institutions.
Recent Initiatives: Recent initiatives include new product development, acquisitions, and strategic partnerships.
Summary
Cumberland Pharmaceuticals is a specialty pharmaceutical company with a focused product portfolio and a hospital-centric strategy. While its niche focus allows for targeted growth, its smaller size and reliance on key products pose challenges. Successful new product launches and strategic acquisitions are vital for continued success, but are not guaranteed. Cumberland is a solid small cap in a tough market.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Third-party market research reports
- Financial databases
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share data is estimates based on available information and may not be precise. Financial data and performance metrics may not be up-to-date due to limitations on access to real-time financial databases.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cumberland Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Nashville, TN, United States | ||
IPO Launch date 2009-08-11 | Founder, Chairman, President & CEO Mr. A. J. Kazimi MBA | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 91 | Website https://www.cumberlandpharma.com |
Full time employees 91 | Website https://www.cumberlandpharma.com | ||
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, an injection for the prevention of nausea and vomiting for patients receiving chemotherapy treatment; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of the cardiomyopathy associate with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, and aspirin-exacerbated respiratory disease; and is in Phase II clinical trial for the treatment of systemic sclerosis and idiopathic pulmonary fibrosis. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.